Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 2/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.55 |
| ▸ | KCNN4 | O15554 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5461421 | 0.85 | KCNN4 (0.65) | POLBGSK3AGSK3BKCNN4ALDH1A1 | |
| SCHEMBL5455248 | 0.84 | POLB (0.73) | POLBGSK3AGSK3BKCNN4ALDH1A1 | |
| SCHEMBL5464665 | 0.83 | POLB (0.55) | POLBGSK3AGSK3BKCNN4ALDH1A1 | |
| SCHEMBL5464663 | 0.83 | POLB (0.55) | POLBGSK3AGSK3BKCNN4ALDH1A1 | |
| SCHEMBL5468557 | 0.80 | ALDH1A1 (0.52) | POLBGSK3AGSK3BALDH1A1HDAC1 | |
| SCHEMBL5462616 | 0.79 | GSK3A (0.60) | POLBGSK3AGSK3BALDH1A1PIM1 | |
| SCHEMBL7252535 | 0.76 | GSK3A (0.82) | POLBGSK3AGSK3BALDH1A1PIM1 | |
| SCHEMBL5454942 | 0.76 | PIM1 (0.51) | POLBGSK3AGSK3BKCNN4ALDH1A1 | |
| SCHEMBL5454874 | 0.76 | GSK3A (0.65) | POLBGSK3AGSK3BALDH1A1PIM1 | |
| SCHEMBL5469987 | 0.76 | GSK3A (0.60) | POLBGSK3AGSK3BALDH1A1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-20060111409-A1 | Medicament for treatment of diabetes | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-25 | — | — | US | disclosed |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | MAP3K1, MAP3K7, MAP3K8 | POLB 2247/4885GSK3A 256/4885GSK3B 363/4885 |
| US-20060111409-A1 | Medicament for treatment of diabetes | XDH, SLC5A1, SLC5A2 | POLB 3923/4885GSK3A 586/4885GSK3B 1164/4885 |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | POLB 3649/4885GSK3A 1386/4885GSK3B 2161/4885 |
| US-20060122243-A1 | Antiallergic | EPX, NAT1, HNMT | POLB 3528/4885GSK3A 1357/4885GSK3B 2003/4885 |
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | POLB 3236/4885GSK3A 2857/4885GSK3B 2838/4885 |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | NFATC1, AP1G1, ATF1 | POLB 4012/4885GSK3A 331/4885GSK3B 516/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | POLB 3737/4885GSK3A 1166/4885GSK3B 1949/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | POLB 3792/4885GSK3A 1257/4885GSK3B 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.